Browning William E DDS ,
-
FDA expands Enhertu use in early HER2-positive breast cancer
The FDA’s May 15 approval adds two early-stage breast cancer uses for Enhertu, also known as fam-trastuzumab deruxtecan-nxki. The update matters for some adults with HER2-positive disease, but it does not change screening guidance or replace a discussion about surgery, chemotherapy, and other treatment options with an oncology team.
-
Aurora Sheboygan Prices – AVF UPPER EXTREMITY CRTN SEPERATE ACCESS SITES WITH IMAGING is $30,430.00
At Aurora Medical Center Sheboygan, we prioritize providing our patients with comprehensive financial information upfront. For Charge Code 10007021, regarding AVF UPPER EXTREMITY CRTN SEPERATE ACCESS SITES WITH IMAGING, which is classified under revenue code 360 and associated with CPT code 36837, the designated fee stands at $30,430.00. Our aim through the CompareMedCosts program is to furnish you with all the details you need to make informed healthcare decisions, offering clarity and transparency around the costs associated with your care.
-
Can a Blood Test Replace a Colonoscopy? What the 2026 Update Means
A 2026 American Cancer Society guideline added blood-based screening as a limited option for some average-risk adults. It did not make blood tests a full replacement for colonoscopy or stool-based screening.
-
2026 Marketplace premiums are up for many Americans
Many people shopping for 2026 coverage on the Health Insurance Marketplace will see higher premiums because enhanced federal premium tax credits expired at the end of 2025. The size of the increase depends on income, age, household size, state, and the plan you choose.